Figma Shares Indicated To Open $105/$110
Cosmos Holdings Inc. (COSM) stock has touched a new 52-week low, dipping to $0.34, as the company faces a challenging market environment. With a market capitalization of just $7.36 million and a high beta of 3.9, the stock shows significant volatility. According to InvestingPro analysis, the stock's RSI indicates oversold conditions. Over the past year, Cosmos Holdings, which operates in the pharmaceutical industry, has seen its stock price decline significantly, with a 1-year change showing a decrease of 51.25%. Despite these challenges, the company has maintained revenue growth of 13% over the last twelve months, though operating with thin gross margins of 8.1%. This latest price level reflects investor concerns and market dynamics that have pressured the stock, leading to a notable drop from its previous positions over the year. InvestingPro analysis suggests the stock may be undervalued at current levels, with 15 additional ProTips available for subscribers. The company, along with its stakeholders, is closely monitoring these developments as they unfold in the financial landscape.
In other recent news, Cosmos Health Inc. has announced a delay in its planned securities offering as the company prepares to file its Annual Report on Form 10-K for the fiscal year ending December 31, 2024. Cosmos Health is also advancing its weight management product, CCX0722, to clinical trials, with expectations of a market launch in the first half of 2026. The company has filed two new patent applications for treatments targeting glioma and hematologic malignancies, developed in collaboration with Cloudpharm and the National Hellenic Research Foundation. Additionally, Cosmos Health has secured a 10-year contract manufacturing agreement with Provident Pharmaceuticals through its subsidiary Cana Laboratories, involving the production of 800,000 pharmaceutical product packs annually. Cosmos Health has also filed a new patent application for an allergy inflammation treatment, supported by findings from its AI-powered Cloudscreen drug repurposing platform. These developments underscore Cosmos Health's ongoing efforts in expanding its research, development, and manufacturing capabilities. The announcements reflect the company's strategic moves to enhance its product offerings and secure long-term revenue streams.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.